Disparities in mental health adherence in trans women with HIV.
Transgender women are highly stigmatized members of society, and those living with HIV have even more healthcare barriers to overcome. For HIV-positive trans women, these hurdles include mental health issues and drug use. These disparities are particularly evident in San Francisco, where almost a quarter of trans women were virally detectable as of 2020.
A study published last week by Erin Wilson, Dr.PH, MPH, in BMC Women’s Health aimed to take a closer look to see if mental illness and substance use were associated with a higher HIV viral load in trans women living in this city.
Participants for this study were recruited through public HIV-care clinics in San Francisco from January to April 2022. Wilson and her team settled on a group of 42 HIV-positive trans women. Within this group, 85.7% were trans women of color, 80.9% were aged 40 or older, 88.1% were low-income, and 47.6% were unstably housed.
The study also found that half of the participants had symptoms of depression and anxiety and almost all used substances. These rates were likely exacerbated by receiving little income and unstable housing situations. However, they were not associated with a higher viral load. Most trans women (66.7%) had an undetectable viral load despite the challenges mentioned above. This may be because treatment adherence was surprisingly high – all but one trans woman was regularly taking HIV medication.
This study did reveal a need for better access to mental health and addiction services for trans women living with HIV. Not all who were previously referred received treatment.
Out of the 56% of individuals referred for mental health services in the past year, 44.4% received care. Of the 26 trans women who tested positive for drug use, 34.6% were referred for care. Only 33.3% received care. The researchers believe this may be due to fear of discrimination or clinic staffing shortages.
“We identified significant unmet mental health and substance use services needs and noted racial/ethnic disparities in the context of high HIV care engagement among trans women living with HIV,” the researchers write. “There is a need for interventions to change the system of delivery for people who face structural barriers so that those most in need are able to be engaged.”
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More
HIV Antiretroviral Reduced Alzheimer’s Risk Continuously, Study Shows
May 8th 2025Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.
Read More
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More
HIV Antiretroviral Reduced Alzheimer’s Risk Continuously, Study Shows
May 8th 2025Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.
Read More
2 Commerce Drive
Cranbury, NJ 08512